AU2006233345A1 - Injectable depot formulations and methods for providing sustained release of nanoparticle compositions - Google Patents

Injectable depot formulations and methods for providing sustained release of nanoparticle compositions Download PDF

Info

Publication number
AU2006233345A1
AU2006233345A1 AU2006233345A AU2006233345A AU2006233345A1 AU 2006233345 A1 AU2006233345 A1 AU 2006233345A1 AU 2006233345 A AU2006233345 A AU 2006233345A AU 2006233345 A AU2006233345 A AU 2006233345A AU 2006233345 A1 AU2006233345 A1 AU 2006233345A1
Authority
AU
Australia
Prior art keywords
formulation
ziprasidone
compound
weight
surface stabilizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006233345A
Other languages
English (en)
Inventor
Jaymin Chandrakant Shah
Parang Suresh Shah
Dawn Renee Wagner
Peter Wisniecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU2006233345A1 publication Critical patent/AU2006233345A1/en
Priority to AU2010201801A priority Critical patent/AU2010201801A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2006233345A 2005-04-13 2006-04-10 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions Abandoned AU2006233345A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010201801A AU2010201801A1 (en) 2005-04-13 2010-05-05 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67112405P 2005-04-13 2005-04-13
US60/671,124 2005-04-13
PCT/IB2006/001094 WO2006109183A1 (en) 2005-04-13 2006-04-10 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010201801A Division AU2010201801A1 (en) 2005-04-13 2010-05-05 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Publications (1)

Publication Number Publication Date
AU2006233345A1 true AU2006233345A1 (en) 2006-10-19

Family

ID=36602931

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006233345A Abandoned AU2006233345A1 (en) 2005-04-13 2006-04-10 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
AU2010201801A Abandoned AU2010201801A1 (en) 2005-04-13 2010-05-05 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010201801A Abandoned AU2010201801A1 (en) 2005-04-13 2010-05-05 Injectable depot formulations and methods for providing sustained release of nanoparticle compositions

Country Status (14)

Country Link
US (1) US20080193542A1 (enExample)
EP (1) EP1874268A1 (enExample)
JP (1) JP2008538751A (enExample)
KR (1) KR20070119678A (enExample)
CN (1) CN101166514A (enExample)
AU (2) AU2006233345A1 (enExample)
BR (1) BRPI0609299A2 (enExample)
CA (1) CA2605153A1 (enExample)
IL (1) IL186131A0 (enExample)
MX (1) MX2007012103A (enExample)
NZ (1) NZ561950A (enExample)
RU (1) RU2407529C2 (enExample)
WO (1) WO2006109183A1 (enExample)
ZA (1) ZA200708188B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
KR20080024206A (ko) * 2005-06-20 2008-03-17 엘란 파마 인터내셔널 리미티드 아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
HRP20131128T1 (hr) * 2007-07-12 2013-12-20 Janssen R&D Ireland Kristalni oblik (e) 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
HRP20201241T1 (hr) * 2011-04-15 2020-11-27 Janssen Pharmaceutica N.V. Nanosuspenzije lijeka osušene zamrzavanjem
CN104814926A (zh) * 2015-04-08 2015-08-05 中国药科大学 一种鲁拉西酮纳米混悬剂及其制备方法
US20170079985A1 (en) * 2015-09-21 2017-03-23 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
EP3600258A1 (en) 2017-03-20 2020-02-05 Teva Pharmaceuticals International GmbH Sustained release olanzapine formulaitons
CN109998991A (zh) * 2019-04-28 2019-07-12 中国药科大学 一种盐酸鲁拉西酮长效肌肉注射纳米混悬液及其制备方法
KR102847306B1 (ko) * 2021-08-13 2025-08-18 단국대학교 천안캠퍼스 산학협력단 결정형 몬테루카스트를 포함하는 지속성 현탁 주사제 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
EP1575616A2 (en) * 2002-10-25 2005-09-21 Pfizer Products Inc. Novel injectable depot formulations
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
KR20060115350A (ko) * 2003-09-02 2006-11-08 화이자 프로덕츠 인크. 지프라시돈의 지속 방출형 투여 형태

Also Published As

Publication number Publication date
CN101166514A (zh) 2008-04-23
MX2007012103A (es) 2007-11-20
IL186131A0 (en) 2008-01-20
RU2407529C2 (ru) 2010-12-27
NZ561950A (en) 2010-09-30
RU2007137846A (ru) 2009-06-20
CA2605153A1 (en) 2006-10-19
KR20070119678A (ko) 2007-12-20
ZA200708188B (en) 2008-10-29
AU2010201801A1 (en) 2010-05-27
WO2006109183A1 (en) 2006-10-19
BRPI0609299A2 (pt) 2010-03-23
EP1874268A1 (en) 2008-01-09
US20080193542A1 (en) 2008-08-14
JP2008538751A (ja) 2008-11-06

Similar Documents

Publication Publication Date Title
US20080305161A1 (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
AU2010201801A1 (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US11717481B2 (en) Reduction of flake-like aggregation in nanoparticulate active agent compositions
US20080166411A1 (en) Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles
CA2603189A1 (en) Injectable depot formulations and methods for providing sustained release of poorly soluble drugs comprising nanoparticles
HU226070B1 (en) Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
HU226608B1 (hu) Vízoldhatalan anyagok mikrorészecskéit tartalmazó készítmények és ezek elõállítására szolgáló eljárások
WO2010138661A1 (en) Nanoparticulate anticancer compositions and methods for making the same
KR20170070025A (ko) 아비라테론 아세테이트 제제 및 사용 방법
AU2014302085A1 (en) Nanoparticulate compositions and formulations of piperazine compounds
AU2007257667A1 (en) Nanoparticulate kinase inhibitor formulations
HK1117740A (en) Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
HK1235663A1 (en) Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
HK1235663A (en) Reduction of flake-like aggregation in nanoparticulate meloxicam compositions

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted